Robust polyfunctional CD8+ and CD4+ T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein
Journal of General Virology · 01.09.2025 · 106 (9)
DOI: 10.1099/jgv.0.002142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of General Virology, erschienen am 01.09.2025. Verfasst von Alina Tscherne und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University (LMU Munich), 85764 Oberschleißheim, Germany. Hauptthemen laut MEDLINE: Lassa virus, CD8-Positive T-Lymphocytes, CD4-Positive T-Lymphocytes, Vaccinia virus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung, Wissenschaft und Kultur.
Abstract (Originalsprache)
Lassa virus (LASV) is circulating in rodents in several countries in West Africa and is the causative agent of the zoonotic disease Lassa fever. Several vaccine candidates have been successfully tested in preclinical and clinical research, while no LASV-specific vaccines or antiviral treatments have been licensed to date. Approximately 500,000 human cases of Lassa fever are estimated to occur every year. However, the high percentage (~80%) of asymptomatic cases and the low frequency of reporting systems in endemic regions demonstrate that Lassa fever cases are highly underreported. Given the frequent spread of the virus by travellers to non-endemic regions, the need for effective vaccines and treatments becomes clear. Here, we describe the generation and preclinical evaluation of two recombinant Lassa virus candidate vaccines, MVA-GP and MVA-NP, which are based on the highly attenuated modified vaccinia virus Ankara (MVA) strain. Constructed in the MVA vector, the MVA-GP vaccine delivers the glycoprotein (GP) of the prototype LASV Josiah strain (lineage IV), whereas the MVA-NP vaccine expresses the nucleoprotein (NP) from the Lassa virus Togo strain (lineage VII). Two immunizations of either MVA-GP or MVA-NP induced substantial polyfunctional Lassa virus-specific CD8 + and CD4 + T cell responses, respectively, in humanized HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice (HLA-A*0201/DR1 transgenic mice). The identified human Lassa virus-specific T cell epitopes were in agreement with recently discovered T cell epitopes found in Lassa fever survivors. Further studies are warranted to characterize these recombinant MVA-Lassa virus vaccine candidates in other preclinical models and investigate their potential to be characterized in clinical studies in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Virology, Department of Veterinary Sciences, Ludwig Maximilians University (LMU Munich), 85764 Oberschleißheim, Germany.
- German Centre for Infection Research, Partner Site Munich, 85764 Oberschleißheim, Germany.
- Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
- German Centre for Infection Research, Partner Site Hannover-Braunschweig, 30559 Hannover, Germany.
Förderung
- Bundesministerium für Bildung, Wissenschaft und Kultur
Zitieren
APA
Tscherne, A., Kalodimou, G., Jany, S., Freudenstein, A., Kumar, S., Pilchová, V., Friebis, T., Maiwald, G., Panhofer, I., Sutter, G., & Volz, A. (2025). Robust polyfunctional CD8+ and CD4+ T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein. Journal of General Virology, 106(9). https://doi.org/10.1099/jgv.0.002142
Vancouver
Tscherne A, Kalodimou G, Jany S, Freudenstein A, Kumar S, Pilchová V, et al. Robust polyfunctional CD8+ and CD4+ T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein. Journal of General Virology. 2025;106(9). doi:10.1099/jgv.0.002142
BibTeX
@article{Tscherne2025,
author = {Tscherne, Alina and Kalodimou, Georgia and Jany, Sylvia and Freudenstein, Astrid and Kumar, Satendra and Pilchová, Veronika and Friebis, Theresa and Maiwald, Gabriel and Panhofer, Isabella and Sutter, Gerd and Volz, Asisa},
title = {Robust polyfunctional CD8+ and CD4+ T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein},
journal = {Journal of General Virology},
year = {2025},
volume = {106},
number = {9},
doi = {10.1099/jgv.0.002142}
}
EUVIMED